Core Viewpoint - Hainan Haiyao's new anti-epileptic drug, Paiengabin, is progressing rapidly in clinical trials, with its development being second only to Xenon's XEN1101 globally, indicating a significant opportunity in the anti-epileptic market due to unmet clinical needs and potential overseas value [1][3]. Group 1: Market Potential - The global epilepsy patient population is approximately 51.7 million, with around 9 million in China, highlighting a substantial market for anti-epileptic treatments [1]. - The Chinese anti-epileptic drug market has seen a compound annual growth rate of 2% over the past five years, with a market size of 5.3 billion RMB in 2023, and is expected to reach a scale in the hundred billion range [2]. Group 2: Drug Development and Advantages - Paiengabin, a new generation KCNQ2 channel agonist, shows significant improvements over the first-generation drug Retigabine, including better chemical stability, activity, and safety profile [3][4]. - Non-clinical and early clinical trials indicate that Paiengabin has superior efficacy, distribution, and safety compared to Retigabine, making it a promising option for patients with epilepsy [4]. Group 3: Clinical Progress and Competitive Landscape - Paiengabin is currently the fastest progressing KCNQ channel agonist in clinical trials in China, having successfully completed Phase IIa studies, while the global landscape shows limited competition with only a few candidates in development [5][6]. - The focus on developing effective and safer KCNQ2-targeted anti-epileptic drugs positions Hainan Haiyao favorably in a market with significant unmet needs [5]. Group 4: Strategic Transformation - Hainan Haiyao has adopted a strategy of combining generics with innovation, enhancing its R&D capabilities, and focusing on high-value innovative drugs to drive growth [7]. - The company's commitment to innovation and its robust pipeline are expected to facilitate its entry into the international pharmaceutical market, benefiting a larger patient population [7].

Meeting Details - The fourth extraordinary general meeting of shareholders was held on September 11, 2025, at 15:00 [1] - The meeting was conducted in a hybrid format combining on-site voting and online voting [2] - The meeting was presided over by independent director Ms. Hu Xiuqun due to the absence of the chairman [2] Attendance - A total of 275 shareholders participated, representing 408,289,551 shares, which accounts for 31.4707% of the total shares [3] - Among them, 1 shareholder attended the on-site meeting, representing 400,660,181 shares (30.8826%), while 274 shareholders voted online, representing 7,629,370 shares (0.5881%) [3][5] Resolutions - No resolutions were rejected during the meeting [4] - The meeting did not involve any changes to previous resolutions [4] Voting Results - The meeting approved the election of non-independent directors for the eleventh board of directors [8] - The candidates Mr. Pan Guihao and Ms. Zhang Ran were elected, with their terms starting from the approval date of the meeting [9] Legal Verification - The meeting was witnessed by lawyers from Beijing Dacheng (Haikou) Law Firm, who confirmed that the meeting complied with relevant laws and regulations [10]

证券代码：000566 证券简称：海南海药 公告编号：2025-057 海南海药股份有限公司 2025 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 二、会议召开的情况 1、会议召开的日期、时间： 现场会议召开时间：2025年9月11日下午15：00 网络投票时间：2025年9月11日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025年9月11日 9：15～9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为：2025年9月11日9:15～ 15:00期间的任意时间。 2、召开地点：海南省海口市秀英区南海大道 192 号海药工业园公司会议室 3、召开方式：采用现场表决与网络投票相结合的方式召开 1、参加现场会议和网络投票的股东 275 人，代表股份 408,289,551 股，占上市公司 总股份的 31.4707%。其中：参加现场会议的股东 1 人，代表有效 ...

北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第四次临时股东大会的 法 律 意 见 书 大成 is Dentons' Preferred Law Firm in China. 北京大成（海口）律师事务所 北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第四次临时股东大会 的法律意见书 致：海南海药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性文件的 要求，北京大成（海口）律师事务所（以下简称"本所"）接受海南海药股份有限 公司（以下简称"公司"）的委托，指派律师参加公司2025年第四次临时股东大 会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会所审议的 议案、议案所涉及的事项及内容发表意见。本所律师同意将本法律意见书随本次 股东大会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-056 海南海药股份有限公司 公司将会利用海南自贸港及海南博鳌乐城国际医疗旅游先行区政策资源优 势，持续推进高端医疗器械平台搭建，如有进展公司将会履行信息披露义务，敬 请广大投资者谨慎决策，注意防范投资风险。 特此公告 1 一、协议概况 海南海药股份有限公司（以下简称"海南海药"或"公司"）与海口国家高 新技术产业开发区管理委员会下属子公司海口高新区国科产业控股有限公司（以 下简称"海口国科"）、德国费森尤斯医疗子企业 Xenios AG(以下简称"西恩尤 斯"）拟就 ECMO（体外膜肺氧合）配套的长效、短效膜式氧合器、动静脉插管等 产品开展合作，为推进三方签署正式的合资协议，各方先期签署了《初始合资合 同》。具体内容详见公司分别于 2024 年 11 月 8 日及 11 月 27 日刊载于巨潮资讯 网（http//www.cninfo.com.cn）的《关于签订初始合资合同的公告》和《关于 正式签署初始合资合同的进展公告》。 二、合作进展情况 协议签订后，经过多次谈判，成立条件未能在最后截止日之前获履行、满足、 完成或豁免。公司经审慎研究，决定 ...

本次财报公布的各项数据指标表现一般。其中，毛利率28.3%，同比减16.03%，净利率-38.2%，同比减 6.51%，销售费用、管理费用、财务费用总计2.78亿元，三费占营收比61.63%，同比增19.16%，每股净 资产0.28元，同比减80.33%，每股经营性现金流0.02元，同比增156.13%，每股收益-0.12元，同比增 20.98% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 5.93亿 | 4.5 Z | -24.12% | | 归母浄利润（元） | -21Z- | -1.58亿 | 20.97% | | 扣非净利润(元) | -1.53亿 | -1.81亿 | -17.98% | | 货币资金(元) | 3.38亿 | 3.41亿 | 0.82% | | 应收账款(元) | 3.69亿 | 3.71亿 | 0.44% | | 有息负债 (元) | 33.43亿 | 28.58亿 | -14.52% | | 手利率 | 33.70% | 28.30% | -16.03% | | 净利率 | - ...

Group 1 - The core viewpoint of the article highlights the growth in the number of enterprises in the chemical raw materials and chemical products manufacturing industry, which increased by 1,021 to a total of 26,860 enterprises in the first half of 2025, representing a year-on-year growth of 3.95% [1] - The proportion of chemical raw materials and chemical products manufacturing enterprises in the total industrial enterprises is 5.16% [1] - The report referenced is the "2025-2031 China Basic Chemical Raw Materials Industry Market Supply and Demand Situation and Investment Prospects Analysis Report" published by Zhiyan Consulting [1] Group 2 - The data indicates that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1] - The consulting firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

格隆汇8月26日丨海南海药(000566.SZ)公布2025年半年度报告，上半年公司实现营业收入4.50亿元，同 比下降24.12%；归属于上市公司股东的净利润-1.58亿元；归属于上市公司股东的扣除非经常性损益的 净利润-1.81亿元；基本每股收益-0.1220元。 ...

海南海药8月26日披露半年报，公司上半年实现营业收入4.5亿元，同比下降24.12%；归属于上市公司股 东的净亏损1.58亿元，上年同期亏损2亿元；基本每股收益-0.122元。 ...

海南海药股份有限公司 2025 年半年度财务报告 海南海药股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：海南海药股份有限公司 2025 年 06 月 30 日 海南海药股份有限公司 2025 年半年度财务报告 | 其中：应付利息 | 5,467,146.57 | 5,467,146.57 | | --- | --- | --- | | 应付股利 | 3,975,170.80 | 3,975,170.80 | | 应付手续费及佣金 | | | | 应付分保账款 | | | | 持有待售负债 | | | | 一年内到期的非流动负债 | 703,573,408.19 | 925,094,301.42 | | 其他流动负债 | 17,747,826.78 | 59,761,025.40 | | 流动负债合计 | 4,336,662,450.39 | 4,299,131,641.34 | | 非流动负债： | | | | 保险合同准备金 | | | | 长期借款 | 955, ...